EDAP TMS S.A. ( (EDAP) ) has released its Q3 earnings. Here is a breakdown of the information EDAP TMS S.A. presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
EDAP TMS S.A. is a global leader in robotic energy-based therapies, specializing in minimally invasive medical devices using ultrasound technology, particularly for prostate cancer treatment. The company recently released its third-quarter 2024 financial results, highlighting an 11.6% increase in worldwide revenue compared to the same period in 2023, with significant growth in its HIFU business. Key financial metrics from the report include a 48.2% increase in HIFU revenue year-over-year and a 34% growth in U.S. Focal One HIFU procedures. The company also announced a strategic AI collaboration with Avenda Health to enhance the Focal One Robotic HIFU system. Despite the operational losses, operating expenses rose due to increased investments in Focal One commercial operations. Looking forward, EDAP TMS remains optimistic about enhancing its clinical programs and expanding its Focal One systems, supported by favorable reimbursement adjustments for 2025.
